A peptide derived from erythropoietin, studied for nerve pain and inflammation. FDA lists it in 503A Category 3.
Key takeaway
ARA-290 is an 11-amino-acid peptide modeled on part of erythropoietin. It is designed to engage a tissue-protective receptor without stimulating red blood cell production.
At a glance
| FDA status | Not FDA-approved |
|---|---|
| 503A compounding | 503A Category 3: nominated without adequate support |
| Body areas | Immune & inflammation, Brain, mood & sleep |
| Through ScriptMates | Information only |
| Open questions | None noted |
What is ARA-290 (cibinetide)?
ARA-290 is an 11-amino-acid peptide modeled on part of erythropoietin. It is designed to engage a tissue-protective receptor without stimulating red blood cell production.
It has been studied in small trials for small-fiber neuropathy. It is not approved, and FDA placed it in 503A Category 3 (nominated without adequate support).
Dosage forms
No FDA-approved dosage form. A standardized dosage form for human use was not confirmed from the sources below.
Is ARA-290 (cibinetide) FDA-approved?
Not FDA-approved. In 503A Category 3, which the interim policy does not allow to be compounded.
Can it be prescribed through ScriptMates?
503A Category 3: nominated without adequate support. A partner pharmacy lists it, but it has no lawful 503A pathway today (503A Category 3: nominated without adequate support).
Sources
Checked October 27, 2026. FDA updates these pages, so confirm before relying on them.